B. Bui-Nguyen

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla et al. · The Lancet · 2012 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +9

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

George D. Demetri, Sant P. Chawla, Isabelle Ray‐Coquard et al. · Journal of Clinical Oncology · 2013 · 242 citations

Medicine, Oncology, Pharmacology +17

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Peter Reichardt, Jean‐Yves Blay, Hans Gelderblom et al. · Annals of Oncology · 2012 · 140 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

Antoine Adenis, Jean‐Yves Blay, B. Bui-Nguyen et al. · Annals of Oncology · 2014 · 82 citations · Full text

Medicine, Oncology, Pharmacology +11

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group

Anna Patrikidou, Julien Dômont, Sylvie Chabaud et al. · European Journal of Cancer · 2015 · 82 citations

Medicine, Oncology, Pharmacotherapy +5